Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Number of holders
-
285
-
Total 13F shares, excl. options
-
84,403,188
-
Shares change
-
+461,276
-
Total reported value, excl. options
-
$5,343,315,732
-
Value change
-
+$44,821,938
-
Put/Call ratio
-
67%
-
Number of buys
-
162
-
Number of sells
-
-113
-
Price
-
$63.32
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q2 2023
340 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q2 2023.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 285 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 84,403,188 shares
of 107,800,271 outstanding shares and own 78% of the company stock.
Largest 10 shareholders include FMR LLC (11,183,496 shares), VANGUARD GROUP INC (8,496,036 shares), BlackRock Inc. (7,591,067 shares), WASATCH ADVISORS LP (3,485,019 shares), Bellevue Group AG (3,201,800 shares), STATE STREET CORP (2,105,705 shares), ALLIANCEBERNSTEIN L.P. (2,040,802 shares), JPMORGAN CHASE & CO (1,977,414 shares), Invesco Ltd. (1,974,881 shares), and GEODE CAPITAL MANAGEMENT, LLC (1,836,757 shares).
This table shows the top 285 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.